Jackson Square Partners LLC boosted its holdings in shares of Haemonetics Co. (NYSE:HAE) by 12.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,655,676 shares of the medical instruments supplier’s stock after buying an additional 187,950 shares during the quarter. Jackson Square Partners LLC’s holdings in Haemonetics were worth $144,838,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Riverhead Capital Management LLC grew its position in shares of Haemonetics by 5.0% in the 1st quarter. Riverhead Capital Management LLC now owns 6,271 shares of the medical instruments supplier’s stock valued at $549,000 after buying an additional 300 shares during the last quarter. Williams Jones & Associates LLC grew its position in shares of Haemonetics by 324.4% in the 1st quarter. Williams Jones & Associates LLC now owns 9,550 shares of the medical instruments supplier’s stock valued at $835,000 after buying an additional 7,300 shares during the last quarter. Trexquant Investment LP purchased a new position in shares of Haemonetics in the 1st quarter valued at $1,058,000. Tyers Asset Management LLC grew its position in shares of Haemonetics by 3.6% in the 1st quarter. Tyers Asset Management LLC now owns 5,568 shares of the medical instruments supplier’s stock valued at $487,000 after buying an additional 192 shares during the last quarter. Finally, Hancock Whitney Corp grew its position in shares of Haemonetics by 5.9% in the 1st quarter. Hancock Whitney Corp now owns 7,200 shares of the medical instruments supplier’s stock valued at $630,000 after buying an additional 400 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.
In other news, CEO Christopher Simon sold 2,834 shares of the firm’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $103.38, for a total value of $292,978.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Dan Goldstein sold 3,206 shares of the firm’s stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $88.90, for a total transaction of $285,013.40. The disclosure for this sale can be found here. Insiders sold a total of 98,460 shares of company stock valued at $9,519,721 in the last 90 days. Company insiders own 1.04% of the company’s stock.
Several research analysts have issued reports on HAE shares. Raymond James raised shares of Haemonetics from a “market perform” rating to an “outperform” rating and set a $110.00 price objective on the stock in a research report on Tuesday, May 14th. TheStreet raised shares of Haemonetics from a “c+” rating to a “b-” rating in a research report on Tuesday, May 7th. Barrington Research reissued an “outperform” rating and set a $116.00 price objective (up from $112.00) on shares of Haemonetics in a research report on Wednesday, May 8th. Finally, Zacks Investment Research raised shares of Haemonetics from a “sell” rating to a “hold” rating in a research report on Tuesday, April 9th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Haemonetics presently has a consensus rating of “Buy” and an average price target of $118.60.
Haemonetics stock traded up $2.04 during midday trading on Wednesday, hitting $110.16. 9,401 shares of the company’s stock were exchanged, compared to its average volume of 486,613. Haemonetics Co. has a 12-month low of $80.24 and a 12-month high of $117.56. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.62 and a current ratio of 2.44. The company has a market capitalization of $5.31 billion, a P/E ratio of 46.10, a PEG ratio of 2.62 and a beta of 0.66.
Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Tuesday, May 7th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.55 by $0.06. Haemonetics had a net margin of 5.69% and a return on equity of 18.88%. The company had revenue of $249.30 million for the quarter, compared to the consensus estimate of $250.62 million. During the same period last year, the firm posted $0.43 EPS. Haemonetics’s revenue for the quarter was up 6.7% on a year-over-year basis. As a group, equities analysts expect that Haemonetics Co. will post 2.93 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Jackson Square Partners LLC Grows Holdings in Haemonetics Co. (NYSE:HAE)” was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://transcriptdaily.com/2019/06/12/jackson-square-partners-llc-grows-holdings-in-haemonetics-co-nysehae.html.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Featured Article: The components of the Stochastic Momentum Index
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.